Presentation is loading. Please wait.

Presentation is loading. Please wait.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Published byCoral Carter Modified over 5 years ago

Similar presentations

Presentation on theme: "Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung."— Presentation transcript:

1 Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung Kim, MD, Seonggyu Byeon, MD, Jong-Mu Sun, MD, PhD, Se-hoon Lee, MD, PhD, Jin Seok Ahn, MD, PhD, Keunchil Park, MD, PhD, Yoon-La Choi, MD, PhD, Joungho Han, MD, PhD, Woongyang Park, MD, PhD, Myung-Ju Ahn, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 1, Pages e1-e4 (January 2016) DOI: /j.jtho Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 (A) Tissue section from the pleura of the patient in case 1 (hematoxylin and eosin stain, magnification ×400) that was obtained before AZD9291 treatment and shows metastatic adenocarcinoma. (B) Tissue section obtained from a lung of the patient in case 1 and showing small cell carcinoma (hematoxylin and eosin stain, magnification ×400). (C) Tissue sample from the same lung (CD56 immunohistochemical stain, magnification ×400); CD56-positive staining was obtained when the patient's disease progressed while she was receiving AZD9291 for 14 months. (D) Tissue section from a lung of the patient in case 2 (hematoxylin and eosin stain, magnification ×400) that was obtained before AZD9291 treatment and shows adenocarcinoma. (E) Tissue section from a lung of the patient in case 2 showing small cell carcinoma (hematoxylin and eosin stain, magnification ×400). (F) Tissue section from the same lung (CD56 immunohistochemical stain, magnification ×400); CD56-positive staining was obtained when the patient's disease progressed while she was being given AZD9291 for 18 months. Journal of Thoracic Oncology  , e1-e4DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 In case 1, a next-generation sequence showed persistence of the L858R mutation (B) but loss of the T790M mutation (A). In case 2, a next-generation sequence showed persistence of the exon 19 deletion (C) but loss of the T790M mutation (A). Journal of Thoracic Oncology  , e1-e4DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Computed tomography (CT) scans of the patient in case 1. (A) CT scan before AZD9291 treatment. Multiple pleural nodules and a para-aortic lymph node were noted. (B) CT scan after 2 months of AZD9291 treatment. The extent of the pleural nodules and para-aortic lymph node was decreased. (C) CT scan after 14 months of AZD9291 treatment. A huge left upper lobe and hilar masses were noted. (D) CT scan after two cycles of etoposide and carboplatin chemotherapy. The huge masses were markedly smaller. Journal of Thoracic Oncology  , e1-e4DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

5 Supplemental Figure 1 Computed tomography (CT) scans of the patient in case 2. (A) CT scan before AZD9291 treatment. Multiple lung nodules and masses were noted. (B) CT scan after 2 months of AZD9291 treatment. The extent of the multiple lung nodules and masses was decreased. (C) CT scan after 18 months of AZD9291 treatment. The multiple lung nodules were increased. (D) CT scan after three cycles of etoposide and carboplatin chemotherapy. The multiple nodules were markedly decreased. Journal of Thoracic Oncology  , e1-e4DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

6 Supplemental Figure 2 Next-generation sequences (NGS) of the patients in case 1 and case 2. (A) In case 1, NGS showed persistence of the L858R mutation and EGFR gene amplification. In case 2, NGS showed persistence of the exon 19 deletion. (B) In case 1, EGFR gene amplification was noted. (C) There were no abnormalities of retinoblastoma (RB) genes in either case. Journal of Thoracic Oncology  , e1-e4DOI: ( /j.jtho ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung."

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
BRCA1 Gene Mutation in Thymic Malignant Melanoma

BRCA1 Gene Mutation in Thymic Malignant Melanoma
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.

Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases  Jong-Mu Sun, MD, Wei.
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity 
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer  Haa-Na Song, MD,
BRAF V600E Mutation Is not Always Present as Expected

BRAF V600E Mutation Is not Always Present as Expected
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors 
Volume 140, Issue 2, Pages (August 2011)

Volume 140, Issue 2, Pages (August 2011)
Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Long-Term Follow-up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Implications of the Proper Follow-up Period and Risk Factors for Subsequent.

Similar presentations

Ads by Google